Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ: VTRS )

12.48 -0.08 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,182,645
Open 12.49
Bid (Size) 12.45 (1)
Ask (Size) 12.55 (1)
Prev. Close 12.56
Today's Range 12.39 - 12.68
52wk Range 9.925 - 13.62
Shares Outstanding 1,212,301,241
Dividend Yield 3.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety

Performance

YTD
+9.57%
+9.57%
1 Month
-5.60%
-5.60%
3 Month
+8.05%
+8.05%
6 Month
+17.40%
+17.40%
1 Year
+15.02%
+15.02%

More News

Read More
3 Chart Patterns That Cut Through The Market’s Chaos
Via Talk Markets
Wall Street Closes At Record Highs After Reassurance From Powell: Magnificent 7 Hit $17 Trillion, Treasury Yields Erase Post-Election Spike
Via Benzinga
Peering Into Viatris's Recent Short Interest
Via Benzinga
Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown
Via Benzinga
These 10 Stocks Were S&P 500's Worst Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Via Benzinga
Exposures Product Safety
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via News Direct
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Via Benzinga
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Via Benzinga
3 Top Value Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Via Benzinga
Why Viatris Stock Is Jumping Today
Via The Motley Fool
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Via Benzinga
S&P 500 Four Under Five
Via Talk Markets
Topics Stocks
Exposures US Equities
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Via Benzinga
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.